05B · Claim Check

Claim Check

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 2 min read

Bookmarks need a Mind Club sign-in. How sign-in works

Claim Check across your briefs

Five readouts checked against their registry records today. Two report their registered primaries; both RAS readouts lead with secondary endpoints; one TB trial gives no numbers for its primary.

ReadoutWhat the registry or primary source saysWhat the headline saysVerdict
ERAS-0015 · Erasca AURORAS-1 · NCT06983743 (opens another website in a new tab)Registered as Phase 1. Primaries: dose-limiting toxicities, maximum tolerated dose, recommended dose, adverse events, pharmacokinetics; response rate secondary. N=600 (planned); recruiting; primary completion 05.2028.Confirmed response rate 44% (n=25) in pancreatic cancer at 32 mg; no dose-limiting toxicitiesPartial
Daraxonrasib + chemotherapy · Revolution Medicines RMC-GI-102 · NCT06445062 (opens another website in a new tab) (our match)Phase 1/2 platform. Primaries for Subprotocols A to F, including the chemotherapy combination: adverse events and dose-limiting toxicities; response, progression-free and overall survival secondary. N=1,130 (planned); recruiting; primary completion 09.30.2028.Response rate 60.7%, median progression-free survival 12.8 months (n=61)Partial
Xanamem · Actinogen XanaMIA · NCT06125951 (opens another website in a new tab)Phase 2/3. Primaries: CDR-SB change at 36 weeks; adverse events. N=247; active, not recruiting; primary completion 09.22.2026.Primary missed: 0.10 points vs placebo, p = 0.65Match
Barzolvolimab · Celldex Atopic dermatitis · NCT06727552 (opens another website in a new tab)Phase 2. Primary: percent change in itch score (PP-NRS) at week 16. N=131; active, not recruiting; primary completion 05.06.2026.Primary missed at both doses; program stoppedMatch
AlpE · BioVersys ENABLE · NCT06748937 (opens another website in a new tab)Phase 2. Primary: early bactericidal activity over 14 days. N=60 (planned). Still reads recruiting past its 03.2026 primary completion date.All regimens bactericidal; no values givenOpen

ClinicalTrials.gov records pulled 11.20.2026 Reg; company releases (11.19 and 11.20) Co. Revolution’s release names the study, RMC-GI-102, but gives no registry number, so its record is our match by drug and design. A verdict compares what was announced with what was registered; it says nothing about whether the drug works.

Open a row on its own (5)